Incannex Healthcare (IXHL) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical developer focused on combination medicines for chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

• Lead programs include IHL-42X (OSA), IHL-675A (inflammatory conditions), and PSX-001 (synthetic psilocybin for anxiety disorder).

• No revenue generated to date; future revenue depends on successful regulatory approval and commercialization of drug candidates.

• Incorporated in Delaware in July 2023 following redomiciliation from Australia.

Financial performance and metrics

• Has not generated any revenue and does not expect significant revenue from drug candidates in the foreseeable future.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders.

• May receive proceeds from the exercise of Pre-Funded Warrants or Series A Warrants, to be used for working capital and general corporate purposes.